cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccyf1bq
title: CCDC 876473: Experimental Crystal Structure Determination

description: Related Article: G.Mehta, R.Samineni, P.Srihari, R.G.Reddy, S.Chakravarty|2012|Org.Biomol.Chem.|10|6830|doi:10.1039/c2ob26107c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qsf
title: CCDC 864645: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy1jdw
title: CCDC 865408: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qtg
title: CCDC 864646: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qvh
title: CCDC 864647: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qwj
title: CCDC 864648: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qxk
title: CCDC 864649: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qyl
title: CCDC 864650: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0qzm
title: CCDC 864651: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccy0r0p
title: CCDC 864652: Experimental Crystal Structure Determination

description: Related Article: M.Nakamura, H.Tahara, K.Takahashi, T.Nagata, H.Uoyama, D.Kuzuhara, S.Mori, T.Okujima, H.Yamada, H.Uno|2012|Org.Biomol.Chem.|10|6840|doi:10.1039/c2ob25930c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccxxls5
title: CCDC 861638: Experimental Crystal Structure Determination

description: Related Article: M.Amat, V.Semak, C.Escolano, E.Molins, J.Bosch|2012|Org.Biomol.Chem.|10|6866|doi:10.1039/c2ob25392e
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccyhn46
title: CCDC 878978: Experimental Crystal Structure Determination

description: Related Article: Xin-Dong Jiang, Ruina Gao, Yi Yue, Guo-Tao Sun, Weili Zhao|2012|Org.Biomol.Chem.|10|6861|doi:10.1039/c2ob26218e
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccx4012
title: CCDC 837993: Experimental Crystal Structure Determination

description: Related Article: J.B.G.Gluyas, C.Burschka, S.Dorrich, J.Vallet, H.Gronemeyer, R.Tacke|2012|Org.Biomol.Chem.|10|6914|doi:10.1039/c2ob25989c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccyr1c2
title: CCDC 886084: Experimental Crystal Structure Determination

description: Related Article: Wen Yang, Da-Ming Du|2012|Org.Biomol.Chem.|10|6876|doi:10.1039/c2ob26068a
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccx4023
title: CCDC 837994: Experimental Crystal Structure Determination

description: Related Article: J.B.G.Gluyas, C.Burschka, S.Dorrich, J.Vallet, H.Gronemeyer, R.Tacke|2012|Org.Biomol.Chem.|10|6914|doi:10.1039/c2ob25989c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccx4034
title: CCDC 837995: Experimental Crystal Structure Determination

description: Related Article: J.B.G.Gluyas, C.Burschka, S.Dorrich, J.Vallet, H.Gronemeyer, R.Tacke|2012|Org.Biomol.Chem.|10|6914|doi:10.1039/c2ob25989c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccx4045
title: CCDC 837996: Experimental Crystal Structure Determination

description: Related Article: J.B.G.Gluyas, C.Burschka, S.Dorrich, J.Vallet, H.Gronemeyer, R.Tacke|2012|Org.Biomol.Chem.|10|6914|doi:10.1039/c2ob25989c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccx4056
title: CCDC 837997: Experimental Crystal Structure Determination

description: Related Article: J.B.G.Gluyas, C.Burschka, S.Dorrich, J.Vallet, H.Gronemeyer, R.Tacke|2012|Org.Biomol.Chem.|10|6914|doi:10.1039/c2ob25989c
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.15468/dl.4q37vc
title: Occurrence Download

description: A dataset containing 1487368 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Human Observation, Material citation, Fossil, Specimen)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Muridae"
 ]
}

 The dataset includes 1487368 records from 2219 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0048382-251009101135966/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ptye8v
title: Occurrence Download

description: A dataset containing 115 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Corymbia papuana (F.Muell.) K.D.Hill & L.A.S.Johnson",
 {
 "or" : [
 "BasisOfRecord is Human Observation",
 "BasisOfRecord is Observation"
 ]
 },
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 115 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0042509-191105090559680/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ser4yh
title: Occurrence Download

description: A dataset containing 439 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Fromundus pygmaeus (Dallas, 1851)"
 ]
}

 The dataset includes 439 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0170643-220831081235567/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pbnma7
title: Occurrence Download

description: A dataset containing 4439117 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON ((26.7542939189847 1.2186193716968,36.9991642472184 13.6345880476356,41.544901412726 10.038706409249,37.5419388341447 2.16847489881781,35.84576825 -7.80500813595271,36.2528491901947 -16.0144737632128,34.2174444892211 -16.5572483501391,27.5006089760084 -8.95840413317107,26.7542939189847 1.2186193716968))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 4439117 records from 894 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0025960-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.z1dhv0
title: Occurrence Download

description: A dataset containing 838175 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Dactylis glomerata L."
 ]
}

 The dataset includes 838175 records from 1278 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009462-200127171203522/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00003366
title: A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects

description: The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.
DOI: 10.25934/00006097
title: A Single Center, Two Part, Randomized, Open Label Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

description: This is a Phase I, single center, two-part, randomized, open label, cross-over study. Part 1 of this study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following repeat dosing of itraconazole, a known strong inhibitor of Cytochrome P450 3A4 (CYP3A4) and a Para-glycoprotein (Pgp) inhibitor. Part 1 will consist of 2 Cohorts with preliminary PK and safety data obtained from Cohort 1 informing Cohort 2. Part 2 (one Cohort) of the study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following repeat dosing of rifampicin, a known potent inducer of CYP3A4. In vitro inhibition data indicate CYP3A4 may be the major route of clearance for GSK525762 and co-administration of drug therapies which modulate CYP3A4 (i.e.CYP3A4 inhibitors and inducers) is likely to alter the exposure of GSK525762 (i.e. increase or decrease exposure, respectively). The data generated from this current study to justify exclusion criteria on concomitant medications which affect CYP3A4 or Pgp and also inform potential dose modification in case of co-administration with medication affecting CYP3A4 activity. All subjects will undergo a screening visit within 28 days of the first dose of study drug followed by one treatment period and a follow-up visit 7-10 days after the last dose of GSK525762. Subjects in Part 1 will participate in the study for up to 45 days and subjects in Part 2 will participate for up to 56 days.
DOI: 10.25934/00002166
title: An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH)

description: This study is a Phase IV, open-label, single-arm study to assess the safety and the necessity of dose adjustment after switching to FLOLAN injection prepared with the reformulated diluent in Japanese patients with PAH who are receiving higher doses of FLOLAN injection than in other countries. The objective is to evaluate the safety and tolerability of the thermostable formulation of FLOLAN injection (that is [i.e.], FLOLAN injection prepared with the reformulated diluent) when switched from the existing FLOLAN injection treatment (i.e., FLOLAN injection prepared with the currently marketed diluent). The study will include a screening visit, a run-in period of a maximum of 4 weeks with the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent), a 4-week treatment period with the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) and a one-week follow-up visit. Adequate number of subjects will be enrolled in the study in order to have 10 subjects to complete assessments at 4 weeks, including at least 5 subjects as a subset of subjects who consent to undergo right heart catheterisation (RHC) over 24-hour and at Week 4. FLOLAN is a registered trademark of the GlaxoSmithKline [GSK] group of companies.
DOI: 10.25934/00002165
title: A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban

description: The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat dosing at higher doses in women with this compound. This study is a 14 day, randomized, placebo-controlled, double blind (sponsor unblind), repeat dose, ascending cohort, dose escalation study in healthy, female volunteers. Upon successful completion of the Screening period, a subject will be enrolled in the study. The study will be composed of three periods: Screening, Treatment and Follow-up. A subject's total time involved in the study will be approximately six weeks. Cohorts will be conducted sequentially. Each subject will be enrolled in only one cohort. Ten subjects will be enrolled in each cohort and randomized to epelsiban (n=8) or placebo (n=2).
DOI: 10.25934/00003789
title: A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects

description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3-Kinase delta inhibitor being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airway diseases. The study will be conducted at a single centre and in 3 Parts. The aim of Part A and B of the study are to assess the safety, tolerability and pharmacokinetics (PK) single and repeat doses of a new formulation of GSK2269557 administered via the ELLIPTA dry powder inhaler (DPI) to healthy subjects. This is the first study in which GSK2269557 will be administered via the ELLIPTA DPI. Part C of the study will investigate the proportion of the systemic exposure that post inhalation is due to the swallowed fraction of the inhaled dose. Part C will also be conducted using the ELLIPTA device and magnesium stearate formulation. Part A will be conducted first. Part B and Part C may be run sequentially or in parallel. Part A is a randomized, double blind, placebo controlled, single dose, dose escalating incomplete block 2-period crossover study in healthy subjects. Subjects will be randomized to receive either one dose strength of GSK2269557 and placebo utilizing placebo replacement, or will receive both active dose strengths. Part B is a randomized, double blind, placebo controlled, repeat dose study in healthy Subjects. Subjects will be randomized to receive either repeat doses of GSK2269557 or placebo for 10 days. Part C is a, randomized, open-label, crossover design to assess the systemic exposure of single doses of GSK2269557 administered via the ELLIPTA DPI to healthy subjects, with and without ingestion of activated charcoal. ELLIPTA is the registered trademark of GlaxoSmithKline groups of companies.
DOI: 10.25934/00005082
title: A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

description: GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease. GSK1278863 has been given as a once daily regimen in clinical studies to date. However, physicians in countries that use a three-times weekly hemodialysis schedule prefer to give the anemia medicine at the same time as the dialysis session. This study will test how well GSK1278863 can maintain hemoglobin levels when given three-times weekly, for 29 days. This study will describe the relationship between hemoglobin and GSK1278863 given three-times weekly. The data from this study will allow for conversion of once daily doses to three-times weekly doses.
DOI: 10.15468/dl.q5br95
title: Occurrence Download

description: A dataset containing 2458818886 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Animalia"
 ]
}

 The dataset includes 2458818886 records from 51012 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001923-241125135418005/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.gexyre
title: Occurrence Download

description: A dataset containing 414 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Peru",
 "StateProvince is arequipa",
 "HasCoordinate is true",
 "TaxonKey is Metallura phoebe (R.Lesson & Delattre, 1839)",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 414 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001475-190813142620410/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xw56p2
title: Occurrence Download

description: A dataset containing 2195 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Viverricula indica (É.Geoffroy Saint-Hilaire, 1803)"
 ]
}

 The dataset includes 2195 records from 65 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0005737-240229165702484/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.